Non-Disclosure Agreement
Physical Development Services
Custom Formulation Development, Reformulation Development, Reverse Engineering, Stability Testing, Project Management, and Lab Batch Production
Section 1
Parties and Recitals
Recitals
WHEREAS, the Consultant provides specialised cosmetic product development and reformulation services, including custom formulation development, reverse engineering, manufacturing process development, stability testing, project management, and lab batch production services;
WHEREAS, the Client desires to engage the Consultant’s services for product development, physical reformulation, or related physical cosmetic science services;
WHEREAS, during the course of the engagement, both parties will exchange highly sensitive and proprietary information including product concepts, formulation data, physical samples, manufacturing processes, supplier relationships, business strategies, market intelligence, and technical methodologies;
WHEREAS, the protection of confidential information is critical to both parties’ commercial success and competitive advantage in the global cosmetics industry;
NOW THEREFORE, in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the parties agree as follows:
Contents
Section 2
Definitions
“Confidential Information”
Means any and all non-public, proprietary, or confidential information disclosed by either party to the other, whether orally, in writing, electronically, visually, or in any other form, including but not limited to:
- •Cosmetic and personal care product formulations, including ingredient lists, percentages, processing methods, and technical specifications
- •Physical samples, prototypes, and benchmark products provided for analysis
- •Manufacturing processes, procedures, techniques, scale-up parameters, and know-how
- •Intellectual property, trade secrets, proprietary methodologies, and technical data
- •Supplier relationships, ingredient sourcing information, and pricing structures
- •Stability testing data, preservative efficacy results, and performance data
- •Customer lists, business relationships, and distribution strategies
- •Regulatory compliance strategies, testing protocols, and safety assessments
- •Market research, competitive analyses, business plans, and strategic information
- •Financial information, cost structures, and commercial terms
- •Research and development data, experimental results, and laboratory findings
- •and any information marked, designated, or reasonably understood to be confidential.
“Permitted Purpose”
Means the legitimate business purpose for which Confidential Information is disclosed, specifically relating to the provision or receipt of physical cosmetic product development services.
“Disclosing Party”
Means the party disclosing Confidential Information.
“Receiving Party”
Means the party receiving Confidential Information.
Section 3
Confidentiality Obligations
Non-Disclosure
The Receiving Party agrees to hold all Confidential Information in strict confidence and shall not disclose, reveal, or make available such information to any third party without the prior written consent of the Disclosing Party.
Non-Use
The Receiving Party shall not use Confidential Information for any purpose other than the Permitted Purpose and shall not use such information for its own benefit or the benefit of any third party.
Standard of Care
The Receiving Party shall exercise the same degree of care to protect Confidential Information as it exercises to protect its own confidential information of a similar nature, but in no event less than reasonable care.
Need-to-Know Basis
The Receiving Party may disclose Confidential Information only to its employees, consultants, advisors, or agents who (a) have a legitimate need to know such information for the Permitted Purpose, (b) have been informed of the confidential nature of such information, and (c) are bound by confidentiality obligations at least as restrictive as those contained herein.
Section 4
Exceptions to Confidentiality
The obligations set forth in Section 3 shall not apply to information that:
4.1 Public Domain
Is or becomes generally available to the public through no breach of this Agreement by the Receiving Party.
4.2 Prior Knowledge
Was known to the Receiving Party prior to disclosure, as evidenced by written records predating such disclosure.
4.3 Independent Development
Is independently developed by the Receiving Party without use of or reference to the Confidential Information, as evidenced by written records.
4.4 Third Party Disclosure
Is rightfully received by the Receiving Party from a third party without breach of any confidentiality obligation.
4.5 Required Disclosure
Is required to be disclosed by law, regulation, court order, or governmental authority, provided that the Receiving Party gives the Disclosing Party reasonable advance notice (where legally permissible) to enable the Disclosing Party to seek protective measures.
Section 5
Intellectual Property Rights
5.2 Client Formulations
5.3 Developed IP
5.4 Consultant’s General Knowledge
5.5 Benchmark Products
5.6 Research and Educational Use
Section 6
Regulatory Compliance
Australian Compliance
Both parties acknowledge their obligations under Australian law, including but not limited to the Privacy Act 1988 (Cth), Competition and Consumer Act 2010 (Cth), Therapeutic Goods Act 1989 (Cth), and applicable state legislation.
International Compliance
For worldwide services, both parties shall comply with applicable international regulations, including but not limited to European Union Cosmetics Regulation, United States FDA regulations, Health Canada regulations, and other applicable jurisdiction-specific requirements.
AICIS Compliance
The Consultant maintains compliance with the Australian Industrial Chemicals Introduction Scheme (AICIS) and shall ensure all recommendations comply with current Australian chemical regulatory requirements.
Section 7
Data Protection and Privacy
Section 8
Return of Materials
Section 9
Term and Termination
Section 10
Remedies
Equitable Relief
The Receiving Party acknowledges that disclosure of Confidential Information would cause irreparable harm to the Disclosing Party for which monetary damages would be inadequate. Therefore, the Disclosing Party shall be entitled to seek equitable relief, including injunction and specific performance, without prejudice to any other rights or remedies.
Monetary Damages
In addition to equitable relief, the Disclosing Party may seek monetary damages, including actual damages suffered, profits gained by the Receiving Party from unauthorised use or disclosure, and legal costs and expenses incurred in enforcing this Agreement.
Liquidated Damages
For breach of confidentiality obligations, the Receiving Party shall pay liquidated damages of AUD $5,000 per incident, which the parties agree represents a reasonable estimate of the harm likely to result from such breach.
Section 11
Governing Law and Jurisdiction
Section 12
General Provisions
12.1 Entire Agreement
This Agreement constitutes the entire agreement between the parties with respect to confidentiality and supersedes all prior agreements, understandings, and communications on this subject, whether written or oral.
12.2 Amendment
This Agreement may be amended only by a written instrument signed by both parties.
12.3 Severability
If any provision is held to be invalid or unenforceable, the remaining provisions shall continue in full force and effect.
12.4 Waiver
No waiver of any provision shall be deemed or shall constitute a waiver of any other provision.
12.5 Assignment
Neither party may assign this Agreement without the prior written consent of the other party.
12.6 Counterparts
This Agreement may be executed in counterparts (including electronic counterparts), each of which shall be deemed an original.
12.7 Electronic Signatures
The parties agree that electronic signatures shall have the same legal effect as handwritten signatures.
Acknowledgement
Signatures
By signing below, the parties acknowledge that they have read, understood, and agree to be bound by the terms and conditions of this Agreement. This Agreement has been prepared in accordance with Australian law and international best practices for cosmetic science consultancy services. Legal advice should be sought before execution.
Consultant Signature
Sweet Little Crumb / This Formulating Life
